Contract manufacturing organisations (CMOs) are operating in an increasingly demanding space. Low volume, complex targeted therapies are dominating drug development pipelines, meaning API manufacturers must be flexible enough to offer a wide range of chemistries and scales of manufacture to accommodate their customers’ requirements.

In the second part of a contract manufacturing roundtable in Manufacturing Chemist our CEO, Kevin Cook, discusses how contract partners need to adapt to the new landscape and take advantage of opportunities for growth and development. Read the full article here: http://bit.ly/2rUmZjm.